BASF Pharma Ingredients and Services - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

BASF Pharma Ingredients and Services


Ludiflash® is a combined filler, binder and disintegrant, designed to dissolve in the mouth within seconds.

Ludiflash® comprises the following ingredients: 90 percent Mannitol, a fast-dissolving filler with a mildly sweet taste; 5 percent Kollidon® CL-SF (crospovidone), a superior tablet disintegrant that is effective even with very little liquid; and 5 percent Kollicoat® SR 30 D (polyvinyl acetate), a hydrophobic binder. Each component complies with all leading pharmacopoeia monographs. Plus, the fast-disintegrating, fast-acting formulations created with Ludiflash® offer an exceptionally smooth and creamy mouthfeel – enhancing patient compliance.

Ludiflash® delivers tangible benefits to manufacturers, exhibiting good flowability, compressibility and stability. The compound’s low hygroscopicity ensures the stability of the active ingredient and of the tablet itself.

Ludiflash® is suitable for direct compression and roller compaction, and can be deployed in wet-granulation processes. Blends can be processed on standard tableting machines or used in the form of granulate or powder. When a standard tableting process is used, Ludiflash® ensures excellent uniformity, even at high speeds: creating compact and highly porous tablets that offer exceptional hardness and low friability, making them suitable for polyethylene containers and push-through blisters.

www.pharma-ingredients.basf.com/Ludiflash/Home.aspx

pharma-ingredients@basf.com

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
30%
Breakthrough designations
9%
Protecting the supply chain
39%
Expedited reviews of drug submissions
9%
More stakeholder involvement
13%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here